AHA 2016’s
superstars:
FUTURE, EUCLID, ART,
PRECISION and GLAGOV
Find out why they are
practice-changers.
Special feature.
4–10
Association of systolic blood
pressure variability with
mortality, coronary heart disease,
stroke, and renal disease
Journal of the American
College of Cardiology
Results showed that the higher
the variability (measured in
standard deviation quartiles),
the greater the association
with all-cause mortality, CHD, stroke,
and ERSD.
11
Coupling data mining and
laboratory experiments to discover
drug interactions causing QT
prolongation
Journal of the American
College of Cardiology
The use of data combined with
laboratory experiments can identify
QT-DDIs. There is a significantly
increased risk of a prolonged QT
interval in patients taking ceftriaxone
and lansoprazole in combination.
12
Retinal vessel calibers in predicting
long-term cardiovascular
outcomes: the Atherosclerosis Risk
in Communities Study
Circulation
This study validates the incremental
benefit of retinal vessel caliber
measurement for evaluating risk for
ischemic stroke and death in the general
population. It appears to be of particular
value in predicting risk of coronary heart
disease in women classified as low-
risk by the 2013 PCE.
14
Life expectancy after myocardial
infarction, according to hospital
performance
The New England
Journal of Medicine
Patients treated in high-performing
hospitals following myocardial
infarction have an extended life
expectancy, consistent with a
lower 30-day risk-standardized
mortality rate, when compared
with patients treated in
low-performing hospitals.
15
In GLAGOV, with
the remarkable lipid
lowering enabled
by the combination
of statin and anti-
PCSK9 antibodies,
we may be wringing
as much “milk out of
the stone” as we can
by lessening lipid
accumulation in
the atheroma.
8
The findings not
only add context
to knowledge
of antiplatelet
monotherapy after
revascularisation
for peripheral artery
disease, but they
also highlight the
need formore trials
of antithrombotic
agents after
revascularisation.
8
FUTUREmay cast
some uncertainty
on the future of the
use of FFR in clinical
practice. Further data
are needed on the
impact on decision
making and how this
could be linked to
adverse outcomes.
9
In the PRECISION
post-hoc analyses of
any CV, GI, or renal
event, celecoxib
had the lowest
risk, naproxen had
intermediate risk and
ibuprofen the highest
risk. These findings
are striking as they
grant absolution to a
drug condemned in
the cardiovascular
community.
9
OPINIONS
RESEARCH NEWS AND VIEWS FROM ELSEVIER
VOL. 1 • No. 3 • 2016
ISSN 2206-4672